C3 淋巴细胞病变:新的治疗模式
Blanca Tarragon Estebanez1, Andrew S Bomback1
1Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Kidney international reports
|March 14, 2024
概括
C3球囊病 (C3G) 是一种由替代补充路径驱动的病. 针对这种途径的新疗法显示出对治疗C3G的希望,与较旧,效率较低的治疗不同.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
- 补充系统生物学 补充系统生物学
背景情况:
- C3球囊病变 (C3G) 的特征在于球囊中孤立或占主导地位的C3沉积.
- 替代补充通路的过活性是C3G中球损伤的主要原因.
- 由于新的治疗发展,C3G的当前治疗范式正在不断发展.
研究的目的:
- 审查C3球囊病的治疗策略的演变.
- 评估非补充向疗法的疗效.
- 突出了对C3G的补充级联向剂的进步.
主要方法:
- 关于C3球囊病治疗现有文献的综述.
- 对补充向剂的临床试验数据的分析.
- 在C3G.病原遗传机制的评估.
主要成果:
- 非补充向疗法在C3G中表现出有限的疗效.
- 新兴的补充向剂正在接受调查.
- 目前正在开发特定疾病的疗法,以应对补充级联.
结论:
- 准补体级联为C3G提供了一个有前途的治疗途径.
- 未来对C3G的治疗可能会专注于补充路径调制.
- 了解病变发生是开发有效C3G疗法的关键.
相关概念视频
Open Angle Glaucoma: Treatment
444
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
444
Angle Closure Glaucoma: Treatment
488
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
488
Alzheimer's Disease: Treatment
186
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186


